Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.48 |
| ▸ | FABP7 | O15540 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28719512 | 1.00 | KMT2A (0.52) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL1808220 | 0.89 | KMT2A (0.53) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL27587878 | 0.89 | KMT2A (0.49) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL27587876 | 0.89 | KMT2A (0.49) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL29468874 | 0.87 | KMT2A (0.48) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL27724920 | 0.87 | KMT2A (0.50) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL28215472 | 0.87 | FABP5 (0.50) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL1000148 | 0.87 | KMT2A (0.48) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL1000147 | 0.87 | KMT2A (0.48) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL27724921 | 0.87 | KMT2A (0.50) | KMT2AFABP5FABP7CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117510352-A | Synthesis method of D-2, 3-diaminopropionic acid | 浙江永太科技股份有限公司 | 2024-02-06 | — | — | CN | disclosed |
| WO-2023060074-A1 | A LIVE CELL ASSAY TO DETERMINE PERMEABILITY OF TEST MOLECULES TO AND/OR WITHIN THE PEPTIDOGLYCAN SCAFFOLD OF BACTERIA CELLS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2023-04-13 | — | — | WO | disclosed |
| EP-0903353-B1 | Imidazolidine derivates, their preparation and use, and pharmaceutical compositions containing them | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-11-25 | — | — | EP | disclosed |
| US-6759424-B2 | 2,5-DIOXOIMIDAZOLIDINE OR 2-THIO-5-OXOIMIDAZOLIDINE DERIVATIVES SUITABLE FOR THE THERAPY AND PROPHYLAXIS OF INFLAMMATORY DISORDERS, FOR EXAMPLE OF RHEUMATOID ARTHRITIS, OR OF ALLERGIC DISORDER | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-06 | — | — | US | disclosed |
| US-6660832-B1 | Cyclic peptide compounds with fused benzene rings; solid phase synthesis thereof; use as antibiotic to treat bacterial infection in mammals; may work by binding to RNA targets | ISIS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| CN-1125054-C | Novel imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them | AVENTIS PHARMACEUTICS GMBH (DE) | 2003-10-22 | — | — | CN | disclosed |
| US-20030125565-A1 | Imidazolidine derivatives, their preparation, their use, and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-07-03 | — | — | US | disclosed |
| US-6423712-B1 | 2,4-Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-07-23 | — | — | US | disclosed |
| WO-1999041227-A1 | TRICYCLIC COMPOUNDS AS GLYCINE TRANSPORT INHIBITORS | ALLELIX NEUROSCIENCE, INC. (US) | 1999-08-19 | — | — | WO | disclosed |
| CN-1218047-A | Novel imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them | HOECHST MARION ROUSSEL DE GMBH (DE) | 1999-06-02 | — | — | CN | disclosed |
| EP-0903353-A1 | Imidazolidine derivates, their preparation and use, and pharmaceutical compositions containing them | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125565-A1 | Imidazolidine derivatives, their preparation, their use, and pharmaceutical preparations comprising them | VCAM1, ITGA1, ITGA4 | KMT2A 1175/4885FABP5 2608/4885FABP7 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.